CaMKK2 Inhibition as a Dual-Action Bone Anabolic and Anti-Catabolic Therapy in Osteoporosis
CaMKK2 Inhibition as a Dual-Action Bone Anabolic and Anti-Catabolic Therapy in Osteoporosis
批准号:
9052878
负责人:
Uma Sankar
金额:
$33.73万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-09-18 至 2020-07-31
关键词:
AcidsAdultAgeAgingAllelesArrestinsBiologyBone DiseasesBone GrowthBone Remodelling PathwayBone ResorptionBone remodelingCa(2+)-Calmodulin Dependent Protein KinaseCalcium/calmodulin-dependent protein kinaseCellsCouplingCyclic AMPCyclic AMP-Dependent Protein KinasesDataDevelopmentDiseaseFamily memberFractureGenerationsGoalsHormonesHourHumanInvestigationKnockout MiceLDL-Receptor Related Protein 1LabelMechanicsMediatingMedicalMessenger RNAModelingMusOperative Surgical ProceduresOsteoblastsOsteoclastsOsteogenesisOsteopeniaOsteoporosisOvariectomyParathyroid glandPartner in relationshipPathway interactionsPatientsPharmaceutical PreparationsPharmacotherapyPhosphotransferasesPlayPopulationProcessProtein KinaseProteinsProteomicsPublic HealthRNARegulationReportingRoleSamplingSignal PathwaySignal TransductionTeriparatideTestingTherapeuticTumor necrosis factor receptor 11bUnited StatesUp-Regulationagedbasebeta cateninbonebone erosionbone lossbone massbone strengthfluorexonhuman diseaseinhibitor/antagonistinnovationlipoprotein receptor related protein 5long bonenew therapeutic targetnovelnuclear factors of activated T-cellsosteoblast differentiationpublic health relevancesenescencesocioeconomicssubstantia spongiosatherapeutic targettomographytranscription factor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Osteoporosis, a disease characterized by the systemic loss of bone mass and strength resulting in fragility fractures, is rapidly poised to become a major public health threat in the United States. Osteoporosis results from imbalances in bone remodeling, a process characterized by osteoblast-mediated bone synthesis and osteoclast-mediated bone resorption. Because osteoporosis is fairly asymptomatic, and is often detected only after the patient has sustained significant bone erosion, therapies aimed at restoring the eroded bone are equally important as those that target bone resorption. However, unlike the highly efficient repertoire of anti- resorptive drugs that form the mainstay of the current anti-osteoporosis therapy, drugs that stimulate bone formation remain largely underdeveloped. Hence there is a critical need for novel therapeutic targets that will stimulate osteoblast-mediated bone accrual together with the inhibition of osteoclastic bone resorption. Our preliminary studies identify Ca2+/calmodulin (CaM)-dependent protein kinase kinase 2 (CaMKK2) as one such target as its inhibition positively impacts anabolic pathways and negatively impacts catabolic pathways of bone remodeling. Mice null for CaMKK2 possess enhanced trabecular bone mass in their long bones, along with significantly higher numbers of osteoblasts and fewer multinuclear osteoclasts. Moreover, its inhibition offers protection from ovariectomy-induced and age-associated osteoporosis in mice. The proposed studies will enable us to define the precise mechanism by which CaMKK2 regulates osteoblast and osteoclast differentiation and devise potential strategies of its inhibition in the treatment of osteoporosis. Development of CaMKK2 inhibition as a new generation therapeutic target that promotes robust bone mass accrual while inhibiting resorption will represent a major breakthrough in anti-osteoporosis treatment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CaMKK2 Signaling in Osteoarthritis
-
批准号:10348741
-
项目类别:
-
资助金额:$52.53万
-
财政年份:2020
-
负责人:Uma Sankar
-
依托单位:
CaMKK2 Signaling in Osteoarthritis
-
批准号:10376643
-
项目类别:
-
资助金额:$31.39万
-
财政年份:2020
-
负责人:Uma Sankar
-
依托单位:
CaMKK2 Signaling in Osteoarthritis
-
批准号:10577743
-
项目类别:
-
资助金额:$53.06万
-
财政年份:2020
-
负责人:Uma Sankar
-
依托单位:
CaMKK2 Inhibition as a Dual-Action Bone Anabolic and Anti-Catabolic Therapy in Osteoporosis
-
批准号:9146157
-
项目类别:
-
资助金额:$45.08万
-
财政年份:2015
-
负责人:Uma Sankar
-
依托单位:
CaMKK2 Inhibition as a Dual-Action Bone Anabolic and Anti-Catabolic Therapy in Osteoporosis
-
批准号:9761835
-
项目类别:
-
资助金额:$34.04万
-
财政年份:2015
-
负责人:Uma Sankar
-
依托单位:
CaMKK2 Inhibition as a Dual-Action Bone Anabolic and Anti-Catabolic Therapy in Osteoporosis
-
批准号:9320514
-
项目类别:
-
资助金额:$43.87万
-
财政年份:2015
-
负责人:Uma Sankar
-
依托单位:
海外基金